Trichlorethanol

Trichlorethanol

SCHEMBL4450822

ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.ClC(Cl)Cl.OCC(Cl)(Cl)Cl

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 2/20 0.32
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trichlorethanol SCHEMBL325071 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL7261325 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL291748 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL759616 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL1436780 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL8522341 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL16162174 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL88329 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL762332 1.00 LMNA (0.33) LMNATDP1TP53TSHR
Trichlorethanol SCHEMBL6898269 1.00 LMNA (0.33) LMNATDP1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181196-B2 Pharmaceutical compounds KEMOTECH S.R.L. (IT) 2015-11-10 US disclosed
US-20140343294-A1 PHARMACEUTICAL COMPOUNDS KEMOTECH S.R.L. (IT) 2014-11-20 US disclosed
EP-2789619-A1 Pharmaceutical compounds wiht angiogenesis inbhibitory activity Kemotech S.r.l. (IT) 2014-10-15 EP disclosed
US-7566781-B2 Imidazopyridine compound BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-28 US disclosed
CN-100418965-C Imidazopyridine derivatives BANYU PHARMA CO LTD (JP) 2008-09-17 CN disclosed
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide BANYU PHARMACEUTICAL., LTD. (JP) 2007-10-25 US disclosed
CN-1835950-A Imidazopyridine derivatives BANYU PHARMA CO LTD (JP) 2006-09-20 CN disclosed
EP-1657242-A1 IMIDAZOPYRIDINE DERIVATIVES Banyu Pharmaceutical Co., Ltd. (JP) 2006-05-17 EP disclosed
CN-1235897-C 4-beta-amino-saccharidoid side chain-4-dehydro-4'-demethylpodoph-yllotoxin derivative with antineoplastic activity and its synthesizing process SHANGHAI INST PHARM INDUSTRY (CN) 2006-01-11 CN disclosed
CN-1331078-A 4-beta-amino-saccharidoid side chain-4-dehydro-4'-demethylpodoph-yllotoxin derivative with antineoplastic activity and its synthesizing process SHANGHAI INST PHARM INDUSTRY (CN) 2002-01-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249659-A1 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide MC1R, MCHR2, MCHR1 LMNA 3634/4885TDP1 3482/4885TP53 4860/4885
US-20140343294-A1 PHARMACEUTICAL COMPOUNDS CYP3A43, CYP2D6, CYP2C9 LMNA 2488/4885TDP1 3972/4885TP53 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.